{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:15Z","timestamp":1787870295862,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00771-3","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:01Z","timestamp":1752836041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Attitudes and eligibility of long-acting cabotegravir\/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Punnathorn","family":"Auaboonkanok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wipaporn Natalie","family":"Songtaweesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvaporn","family":"Anugulruengkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutima","family":"Saisaengjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnaphak","family":"Seesuksai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirinya","family":"Teeraananchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"771_CR1","unstructured":"HIV indicators [Internet]. UNAIDS. 2023 [cited January 2025]. Available from: https:\/\/aidsinfo.unaids.org\/"},{"key":"771_CR2","volume-title":"The urgency of now: AIDS at a crossroads","author":"H Marais","year":"2024","unstructured":"Marais H. The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV\/AIDS; 2024."},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","volume":"8","author":"WM Han","year":"2021","unstructured":"Han WM, Law MG, Egger M, Wools-Kaloustian K, Moore R, McGowan C, et al. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV. 2021;8:e766\u201375.","journal-title":"Lancet HIV"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2055-6640(20)30276-4","volume":"5","author":"S Teeraananchai","year":"2019","unstructured":"Teeraananchai S, Puthanakit T, Kerr SJ, Chaivooth S, Kiertiburanakul S, Chokephaibulkit K, et al. Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS program. J Virus Erad. 2019;5:33\u201340.","journal-title":"J Virus Erad"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/COH.0000000000000880","volume":"19","author":"N Rakhmanina","year":"2024","unstructured":"Rakhmanina N, Foster C, Agwu A. Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here? Curr Opin HIV AIDS. 2024;19:368\u201376.","journal-title":"Curr Opin HIV AIDS"},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10461-012-0364-1","volume":"17","author":"K MacDonell","year":"2013","unstructured":"MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17:86\u201393.","journal-title":"AIDS Behav"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMms2412286","volume":"392","author":"W Byanyima","year":"2025","unstructured":"Byanyima W, Bekker LG, Kavanagh MM. Long-Acting HIV medicines and the pandemic inequality Cycle - Rethinking access. N Engl J Med. 2025;392:90\u20136.","journal-title":"N Engl J Med"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396:1994\u20132005.","journal-title":"Lancet"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, et al. Long-Acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112\u201323.","journal-title":"N Engl J Med"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","volume":"36","author":"S Swindells","year":"2022","unstructured":"Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. Aids. 2022;36:185\u201394.","journal-title":"Aids"},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","volume":"11","author":"AH Gaur","year":"2024","unstructured":"Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, et al. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017\/MOCHA): a phase 1\/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024;11:e211\u201321.","journal-title":"Lancet HIV"},{"key":"771_CR12","unstructured":"Administration FaD. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use 2023 [package insert]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212888s011lbl.pdf"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/jpids\/piac134","volume":"12","author":"BJ Freij","year":"2023","unstructured":"Freij BJ, Aldrich AM, Ogrin SL, Olivero RM. Long-Acting antiretroviral drug therapy in adolescents: current status and future prospects. J Pediatr Infect Dis Soc. 2023;12:43\u20138.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","volume":"80","author":"ED Weld","year":"2019","unstructured":"Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, et al. Interest of youth living with HIV in Long-Acting antiretrovirals. J Acquir Immune Defic Syndr. 2019;80:190\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s10461-022-03949-2","volume":"27","author":"E Toska","year":"2023","unstructured":"Toska E, Zhou S, Chen-Charles J, Gittings L, Operario D, Cluver L. Factors associated with preferences for Long-Acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa. AIDS Behav. 2023;27:2163\u201375.","journal-title":"AIDS Behav"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish CL, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, et al. Multisite study of women living with hiv\u2019s perceived barriers to, and interest in, Long-Acting injectable antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84:263\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1080\/13691058.2020.1752397","volume":"23","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. I feel empowered: women\u2019s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Cult Health Sex. 2021;23:1066\u201378.","journal-title":"Cult Health Sex"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307.","journal-title":"Infect Genet Evol"},{"key":"771_CR19","volume-title":"RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH","author":"DTA Ghebreyesus","year":"2021","unstructured":"Ghebreyesus DTA, Consolidated guidelines on HIV prevention testing, treatment, service delivery and monitoring. Recommendations for a public health approach. 3 ed. Geneva: World Health Organization; 2021.","edition":"3"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"e26071","DOI":"10.1002\/jia2.26071","volume":"26","author":"S Teeraananchai","year":"2023","unstructured":"Teeraananchai S, Kerr SJ, Ruxrungtham K, Khananuraksa P, Puthanakit T. Long-term outcomes of rapid antiretroviral NNRTI-based initiation among Thai youth living with HIV: a National registry database study. J Int AIDS Soc. 2023;26:e26071.","journal-title":"J Int AIDS Soc"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","volume":"24","author":"C Kityo","year":"2024","unstructured":"Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;24:1083\u201392.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 5","key":"771_CR22","doi-asserted-by":"publisher","first-page":"e25574","DOI":"10.1002\/jia2.25574","volume":"23","author":"S Teeraananchai","year":"2020","unstructured":"Teeraananchai S, Kerr SJ, Khananuraksa P, Ruxrungtham K, Puthanakit T. Rapid antiretroviral initiation among Thai youth living with HIV in the National AIDS programme in the era of treatment at any CD4 cell count: a National registry database study. J Int AIDS Soc. 2020;23(Suppl 5):e25574.","journal-title":"J Int AIDS Soc"},{"key":"771_CR23","unstructured":"Division of AIDS and STIs, Ministry of Public Health, Thailand. Adolescents living with HIV who are currently receiving ART and have achieved viral load suppression.: HIV INFO HUB, Thailand. 2024 [cited 2024. Available from: https:\/\/hivhub.ddc.moph.go.th\/officer\/dashboard\/service_area.php"},{"key":"771_CR24","unstructured":"Thailand Food and Drug Administration. Public Pharmaceutical Regulatory Information: VOCABRIA (PROLONGED-RELEASE SUSPENSION FOR INJECTION): Ministry of Public Health. 2024 [Available from: https:\/\/pertento.fda.moph.go.th\/FDA_INFORMATION_DRUG\/Home\/Phar_Product_Inform_Page?Newcode=U1DR1C1012670003011C"},{"key":"771_CR25","unstructured":"Thailand Food and Drug Administration. Public Pharmaceutical Regulatory Information: REKAMBYS (SUSPENSION FOR INJECTION): Ministry of Public Health. 2024 [Available from: https:\/\/pertento.fda.moph.go.th\/FDA_INFORMATION_DRUG\/Home\/Phar_Product_Inform_Page?Newcode=U1DR1C1012671507811C"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/QAD.0000000000003620","volume":"37","author":"D Barthold","year":"2023","unstructured":"Barthold D, Saldarriaga EM, Brah AT, Hauber B, Banerjee P, Fuller SM, et al. Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV. Aids. 2023;37:1545\u201353.","journal-title":"Aids"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1080\/09540121.2021.2001783","volume":"34","author":"CK Campbell","year":"2022","unstructured":"Campbell CK, Dub\u00e9 K, Sauceda JA, Ndukwe S, Saberi P. Antiretroviral therapy experience, satisfaction, and preferences among a diverse sample of young adults living with HIV. AIDS Care. 2022;34:1212\u20138.","journal-title":"AIDS Care"},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/INF.0000000000003059","volume":"40","author":"PR Tsondai","year":"2021","unstructured":"Tsondai PR, Davies MA, Singtoroj T, Maxwell N, McGowan CC, Songtaweesin WN, et al. Improving methods to classify perinatal versus nonperinatal HIV acquisition in young adolescents 10\u201314 years of age. Pediatr Infect Dis J. 2021;40:453\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"771_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/QAI.0000000000002718","volume":"87","author":"C Muccini","year":"2021","unstructured":"Muccini C, Pinyakorn S, Sirivichayakul S, Kroon E, Sacdalan C, Crowell TA, et al. Brief report: prevalence trend of transmitted drug resistance in a prospective cohort of Thai people with acute HIV infection. J Acquir Immune Defic Syndr. 2021;87:1173\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09540121.2013.802280","volume":"26","author":"A Usitalo","year":"2014","unstructured":"Usitalo A, Leister E, Tassiopoulos K, Allison S, Malee K, Paul ME, et al. Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection. AIDS Care. 2014;26:107\u201315.","journal-title":"AIDS Care"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13012-021-01181-5","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Opra Widerquist MA, Lowery J. Conceptualizing outcomes for use with the consolidated framework for implementation research (CFIR): the CFIR outcomes addendum. Implement Sci. 2022;17:7.","journal-title":"Implement Sci"},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10:e332\u201342.","journal-title":"Lancet HIV"},{"key":"771_CR33","unstructured":"Fionnuala Ryan NEM, Jayadel H, Ayers S, Calorine Foster. Eligibility for long acting cabotegravir\/ rilpivirine in youth aged 12\u201325 living with perinatally-acquired HIV. BHIVA Spring Conference. 2023; Gateshead, United Kingdom2023."},{"key":"771_CR34","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","volume":"76","author":"KA Christopoulos","year":"2023","unstructured":"Christopoulos KA, Grochowski J, Mayorga-Munoz F, Hickey MD, Imbert E, Szumowski JD, et al. First demonstration project of Long-Acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. Clin Infect Dis. 2023;76:e645\u201351.","journal-title":"Clin Infect Dis"},{"key":"771_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/jpids\/piae033","volume":"13","author":"A Rousseau","year":"2024","unstructured":"Rousseau A, McGrath E, Benjamins L, Cockern S, Meade J, Houston K, et al. Off-label use of Long-Acting injectable antiretroviral therapy: A single center retrospective review of youth living with HIV with detectable HIV RNA starting injectable therapy. J Pediatr Infect Dis Soc. 2024;13:285\u20137.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"771_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1468-1293.2010.00828.x","volume":"11","author":"T Puthanakit","year":"2010","unstructured":"Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010;11:565\u201372.","journal-title":"HIV Med"},{"key":"771_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/INF.0b013e3181a458f9","volume":"28","author":"P Jittamala","year":"2009","unstructured":"Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2009;28:826\u201330.","journal-title":"Pediatr Infect Dis J"},{"key":"771_CR38","unstructured":"HIV indicators-viral suppression rate [Internet]. Thai National AIDS Program-Web report. 2023 [cited January 2025]. Available from: http:\/\/napdl.nhso.go.th\/NAPWebReport\/main_rep.jsp"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00771-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:08:42Z","timestamp":1757254122000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00771-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00771-3","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The views expressed in this article are the author\u2019s own and not an official position of the institution or funder.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University and The Kasetsart University Research Ethics Committee. All participants in the clinical cohort provided informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the manuscript for publication. No individual participant data is included, which requires additional consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}